Hugues Bienayme
Chief Scientific Officer
Hugues brings over 30 years of R&D leadership experience in the pharmaceutical (Aventis, Pierre Fabre) and biotechnology sectors (Chrysalon, Urogene). In 2007, he founded Orphelia Pharma, a company committed to delivering essential treatments for rare pediatric diseases. Under his leadership, the company brought two key medicines to patients: Kigabeq (in epilepsy) and Kimozo (in oncology).
He joined Orphalan in 2025, following the integration of Orphelia into the Orphalan group.
Hugues holds a PhD in Organic Chemistry from the University of Paris and an engineering degree from the École Normale Supérieure in Saint‑Cloud.
